On Monday, Shares of Genworth Financial Inc (NYSE:GNW), added 2.16% and closed at $5.21 in the last trading session. The last trading range of the stock ranges between $5.13 and $5.27. The company’s Market capitalization is $2.59 Billion with the total Outstanding Shares of 498.34 million. Genworth Financial, Inc. provides insurance and homeownership solutions in the United States and internationally. It operates through five segments: U.S. Mortgage Insurance, Canada Mortgage Insurance, Australia Mortgage Insurance, U.S. Life Insurance, and Runoff. The U.S. Mortgage Insurance segment offers mortgage insurance products mainly insure prime-based and individually underwritten residential mortgage loans. The Canada Mortgage Insurance segment provides flow mortgage insurance; and bulk mortgage insurance products and services that aid in the sale of mortgages to the capital markets, in addition to assists lenders manage capital and risk in Canada. The Australia Mortgage Insurance segment offers flow mortgage insurance, in addition to bulk mortgage insurance that aids in the sale of mortgages to the capital markets in Australia. The U.S. Life Insurance segment offers long-term care insurance products, in addition to service traditional life insurance and fixed annuity products in the United States. The Runoff segment covers non-planned products, which mainly include variable annuity, variable life insurance, institutional, corporate-owned life insurance, and accident and health insurance products. This segments institutional products include funding agreements, funding agreements backing notes, and guaranteed investment contracts.
Patterson-UTI Energy, Inc. (NASDAQ:PTEN), jumped 4.47% and closed at $24.05 in the last trading session. The last trading range of the stock ranges between $23.38 and $24.15. The company’s Market capitalization is $3.55 Billion with the total Outstanding Shares of 147.73 million. During the 52-week trading session the minimum price at which share price traded, registered at $10.94 and reached to max level of $24.15. PATTERSON-UTI ENERGY, INC. (PTEN) recently stated that for the month of September 2016, the Company had an average of 62 drilling rigs operating in the United States and two rigs in Canada. For the three months ended September 30, 2016, the Company had an average of 60 drilling rigs operating in the United States and two rigs in Canada.
Average drilling rigs operating stated in the Company’s monthly declarements represent the average number of the Company’s drilling rigs that were operating under a drilling contract. The Company cautioned that numerous factors in addition to average drilling rigs operating can impact the Company’s operating results and that a particular trend in the number of drilling rigs operating may or may not indicate a trend in or be indicative of the Company’s financial performance. The Company intends to continue providing monthly updates on drilling rigs operating shortly after the end of each month.
On the otherhand Peregrine Pharmaceuticals (NASDAQ:PPHM), dropped -9.17% and closed at $0.394 in the last trading session. The last trading range of the stock ranges between $0.37 and $0.44. The company’s Market capitalization is $95.83 Billion with the total Outstanding Shares of 242.38 million. During the 52-week trading session the minimum price at which share price traded, registered at $0.29 and reached to max level of $1.33. Peregrine Pharmaceuticals, Inc. (PPHM) (PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, recently stated that top-line data from the Phase III SUNRISE trial of bavituximab in patients with formerly treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) were presented in an oral presentation at the European Society for Medical Oncology (ESMO) 2016 Congress. The presentation included interim efficacy and safety outcomes, in addition to initial findings from the company’s ongoing biomarker analysis of samples collected during the study. The SUNRISE Phase III trial was suspended earlier this year based on a pre-specified interim analysis although patient treatment and follow-up in the study were allowed to continue. The pre-planned biomarker analysis has been taking place as patient follow-up has continued and available results were evaluated as part of the recent top-line data analysis.
The study protocol pre-specified the collection of thousands of patient samples for exploratory analyses over a wide range of possible biomarkers, counting pre-treatment levels of beta-2 glycoprotein-1 (β2GP1). Data presented at ESMO demonstrated that patients with pre-treatment β2GP1 levels between 200 and 240 (representing about 30% of randomized patients) achieved a statistically significant, 5.5-month improvement (13.2 months vs. 7.7 months) in median overall survival (OS) as contrast to patients in the control group with the same range of β2GP1 levels [p = 0.049; hazard ratio (HR) = 0.67]. A similar trend was observed with pre-treatment β2GP1 levels ≥ 200 µg/mL (representing about 50% of randomized patients) with 11.9 months vs. 10.1 months median OS in favor of the bavituximab-containing group (p = 0.155; HR = 0.81). Taken together, this strongly suggests β2GP1 levels may be useful for identifying patients who are more likely to benefit from a bavituximab containing therapeutic regimen. Numerous additional biomarkers are presently being analyzed with the aim of developing a multi-marker signature that can potentially identify patients that are likely to receive noteworthyclinical benefit from a bavituximab-containing therapeutic regimen.